| 1 |
31922424 | Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma. | 2020 Feb |
1 |
| 2 |
32546645 | Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. | 2020 Sep 15 |
1 |
| 3 |
32947305 | The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials. | 2020 Sep/Oct |
1 |
| 4 |
30401688 | Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. | 2019 Feb 15 |
1 |
| 5 |
31054006 | Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand? | 2019 May 3 |
1 |
| 6 |
31348025 | The current role for adjuvant and neoadjuvant therapy in renal cell cancer. | 2019 Nov |
1 |
| 7 |
28479237 | Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. | 2018 Jan |
1 |
| 8 |
29374054 | Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. | 2018 Apr 1 |
1 |
| 9 |
29877179 | Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. | 2018 Jun |
1 |
| 10 |
30412222 | Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. | 2018 Oct 1 |
1 |
| 11 |
29662544 | Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. | 2017 Aug |
1 |
| 12 |
27930642 | Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough? | 2016 Nov |
1 |